# PanTracer

Source: https://onco.cc/drugs/neogenomics-pantracer/  
OnCo record `neogenomics-pantracer` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NeoGenomics' family of large gene tests for solid tumours, from a tissue sample or a blood draw.

## Summary

PanTracer is NeoGenomics' portfolio of comprehensive genomic profiling tests for solid tumours. PanTracer Tissue sequences 517 genes in DNA and RNA for single-nucleotide variants, insertions and deletions, copy number changes, RNA fusions and splice variants, with microsatellite instability and tumour mutational burden, in 8 to 10 days; PanTracer Tissue + HRD adds a homologous recombination deficiency score (BRCA1/2 and a genomic instability score from loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions), validated for primary epithelial ovarian tumours; PanTracer Pro adds HRD and cancer-type-directed immunohistochemistry to the tissue test in one order. PanTracer LBx sequences 514 genes from circulating tumour DNA in 7 days, without RNA sequencing or HRD. NeoGenomics lists PanTracer Tissue and Pro as New York approved, and the HRD and LBx tests as not.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Also known as: NeoGenomics PanTracer; NEO PanTracer Tissue; NEO PanTracer Pro; NEO PanTracer LBx
- Tags: test
- Brand: PanTracer
- Modality: Comprehensive genomic profiling tests for solid tumours (tissue and blood)
- Mechanism: Tissue sequencing of 517 genes in DNA and RNA, or blood sequencing of 514 genes in circulating tumour DNA, for single-nucleotide variants, insertions and deletions, copy number changes and fusions.

## Notes

- What a result means: an alteration linked to a drug or trial is reported for the cancer type; a negative blood result does not rule out an alteration in the tumour.

## Sources

- NeoGenomics: PanTracer portfolio: https://www.neogenomics.com/providers/oncology-solutions/pantracer-portfolio
- NeoGenomics: lung cancer testing: https://www.neogenomics.com/providers/oncology-solutions/lung-cancer

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Reference laboratories and companion-diagnostic testing](https://onco.cc/technologies/reference-laboratories/)
- companies: [NeoGenomics](https://onco.cc/companies/neogenomics/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)

---
JSON: https://onco.cc/api/v1/entities/neogenomics-pantracer.json